Inimex receives US$4.5 million in venture financing

Guest Contributor
July 16, 2004

Vancouver-based Inimex Pharmaceuticals Inc has received US$4.5 million in syndicated financing for the lead optimization and pre-clinical development of the first drug based on its innate immunity technology platform. The investment was made by a financing syndicate led by BDC Venture Capital and including the Canadian Medical Discoveries Fund and Working Opportunity Fund. Inimex’s platform was developed in collaboration between company and academic scientists and sponsored by Genome Canada. Inimex is seeking an additional US$2-3 million to fund IND studies and an expansion of its product pipeline....

Other News

Events For Leaders in
Science, Tech, Innovation, and Policy

Discuss and learn from those in the know at our virtual and in-person events.

See Upcoming Events

You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in


By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.